neuropsychiatric symptoms Tagged Articles
New warnings for off-label smoking addiction drug Aplenzin
The antidepressant Aplenzin (bupropion hydrobromide) extended-release tablets has a new black box warning against the use of the drug to help people quit smoking. The drug is approved by the Food and Drug Administration (FDA) only for the treatment of
Support group says Chantix ads conceal important information
WhyQuit, an organization that advocates quitting smoking using the cold turkey method, recently published an article that takes Pfizer to task over its latest Chantix ads. The group claims that the pharmaceutical company’s new television commercials hide information from the
Family of musician killed in Chantix rage sues Pfizer
The family of musician Carter Albrecht has filed a lawsuit in a Dallas federal court against Chantix manufacturer Pfizer Inc. Ken and Judy Albrecht allege that the drug manufacturer is responsible for the musician’s death in 2007 because it marketed
FDA approves stronger, expanded warnings on Chantix labeling
The Food and Drug Administration has approved the new labeling for Chantix packaging. In July, we reported that the agency said it would require stronger warnings on all Chantix labeling, as well as packaging for other smoking cessation drugs Wellbutrin and
